# Olema Oncology

> Olema Oncology is a clinical-stage biopharmaceutical company based in San Francisco that develops targeted small-molecule therapies for ER+/HER2- metastatic breast cancer and other women's cancers. Its lead candidate, palazestrant (OP-1250), is an oral complete estrogen receptor antagonist and selective ER degrader now in two Phase 3 trials, while a second program, OP-3136, is a KAT6 inhibitor in Phase 1. Olema's bet is that better-designed oral endocrine therapy can overcome the resistance that limits today's standard of care.

- **Founded:** 2006
- **Headquarters:** San Francisco, California, United States
- **Founders:** Peter Kushner (Co-founder / Scientific Founder)
- **Team size:** ~96 employees
- **Products:** Palazestrant (OP-1250), OP-3136
- **Notable:** Advanced palazestrant into two Phase 3 trials (OPERA-01 and OPERA-02)., Secured a Novartis collaboration and $250M private placement to fund frontline combination development., Completed a ~$209M Nasdaq IPO in 2020.

## Products & services

- **Palazestrant (OP-1250)** — Lead candidate: an orally available complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD) for ER+/HER2- metastatic breast cancer. In Phase 3 OPERA-01 (monotherapy, 2nd/3rd line) and Phase 3 OPERA-02 (frontline, in combination with ribociclib).
- **OP-3136** — A potent, selective lysine acetyltransferase 6 (KAT6) inhibitor in a Phase 1 clinical study, expanding Olema's reach beyond the estrogen receptor.

## Achievements

- Advanced palazestrant into two Phase 3 trials (OPERA-01 and OPERA-02).
- Secured a Novartis collaboration and $250M private placement to fund frontline combination development.
- Completed a ~$209M Nasdaq IPO in 2020.
- Reported median PFS of 15.5 months for palazestrant plus ribociclib in the 120 mg cohort in early ER+/HER2- mBC data.
- Selected a 90 mg once-daily palazestrant dose for pivotal Phase 3 development.

## Latest updates

- **2026-04** — To present preclinical data for palazestrant and OP-3136 at the 2026 AACR Annual Meeting.
- **2025-12** — Trial-in-progress poster for the Phase 3 OPERA-02 trial of palazestrant plus ribociclib presented at SABCS 2025.
- **2025-10** — New data from the Phase 1b/2 trial of palazestrant plus ribociclib presented at ESMO 2025.
- **2025-06** — Announced palazestrant 90 mg dose selection and trial-in-progress poster at ASCO 2025.
- **2024-12** — Announced Novartis clinical collaboration and supply agreement for ribociclib plus a $250 million equity private placement.

## Links

- Website: https://olema.com
- LinkedIn: https://www.linkedin.com/company/olema-oncology
- Twitter/X: https://twitter.com/OlemaOncology

---

Profile page: https://yespress.io/olema-oncology
Published by YesPress — https://yespress.io
Last updated: 2026-06-20